Neurocrine Bio. (NBIX) PT Raised to $138 at Stifel; Nice Ingrezza Beat and Better TRx Commentary

Neurocrine Biosciences (NBIX) Tops Q2 EPS by 14c

Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $0.63, $0.14 better than the analyst estimate of $0.49. Revenue for the quarter came in at $288.9 million versus the consensus estimate of $274.38 million.

"We helped more tardive dyskinesia patients than ever before as our second quarter results reflect... More